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ABSTRACT
Background: Predictive biomarkers of efficacy and toxicity of bevacizumab have 
not yet been validated. This study assessed the influence of IL-8, eNOS and VEGF-A 
polymorphisms in RAS mutated metastatic colorectal cancer patients receiving 
bevacizumab-based chemotherapy.
Methods: 120 patients treated with first-line combination FOLFOX6 plus 
bevacizumab were included. A historical cohort of 112 RAS mutated colorectal cancer 
patients treated with FOLFOX6 alone served as control group. The following SNPs 
were analyzed: IL-8 c.-251T>A; eNOS c.-786T>C and c.-894G>T; VEGF-A c.936C>T, 
c.958T>C, c.1154A>G and c.2578C>A. Correlation of SNPs, baseline IL-8 serum levels 
and bevacizumab-efficacy was done.
Results: In the bevacizumab group, carriers of the IL-8 alleles c.-251TA+AA 
showed a shorter PFS (P=0.002) and OS (P=0.03) compared to TT alleles. Patients 
with pre-treatment IL-8 < 18.25 pg/ml showed significantly longer median PFS and 
OS (PFS: 10.9 vs 7.6 months, P=0.005; OS: 30.7 vs 18.2 months, P<0.001) compared 
to patients with IL-8 higher levels (>18,25 pg/ml). IL-8 c.-251TA+AA carriers had 
significantly higher IL-8 levels (P<0.0001). Multivariate analysis confirmed association 
of IL-8 polymorphism with PFS, and of IL-8 baseline levels with both PFS and OS. 
IL-8 SNP did not affect the outcome in the control group. The eNOS polymorphism 
c.-894G>T was found associated with higher severe toxicity (P=0.0002) in patients 
carrying the c.-894TT genotype.
Conclusions: Although our data need prospective validation, IL-8 and eNOS SNPs 
may be have a role as predictive biomarkers for bevacizumab efficacy and toxicity.
INTRODUCTION
To date, predictive biomarkers of efficacy and 
toxicity of bevacizumab have not yet been validated 
in metastatic colorectal cancer (mCRC) patients [1]. 
Some evidence suggests that clinical or radiological 
parameters might predict the efficacy of bevacizumab, 
but their clinical implementation has yet to be proven 
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[2–4]. The use of predictive biomarkers might improve 
mCRC patients selection for bevacizumab-based 
treatment. This issue is particularly relevant for RAS 
mutated subset, due to limited availability of effective 
treatment options. Unfortunately, since angiogenesis is 
a multifactorial and host-mediated process, validation 
of such biomarkers is not always easy. The outcome 
of patients treated with bevacizumab-based therapies 
may be related to polymorphisms in genes involved in 
different aspects of angiogenesis, leading to changes in 
vascular endothelial growth factor (VEGF)-dependent and 
independent pathways. A role of VEGF single nucleotide 
polymorphisms (SNPs) has been suggested in colorectal 
cancer with controversial results [5, 6].
While VEGF-A is the target of bevacizumab, it 
is conceivable that resistance to treatment may also be 
linked to an angiogenic switch due to up-regulation of 
VEGF-independent pathways. For instance, interleukin-8 
(IL-8) induces angiogenesis and increases endothelial 
permeability in absence of hypoxic environment [7–10]. 
The IL-8 c.-251T>A polymorphism seems to be associated 
to variations of promoter transcriptional activity and to 
higher levels of circulating IL-8 [11–15]. Moreover, VEGF 
up-regulate the expression of nitric oxide synthase [16, 
17], resulting in the release of endothelium-derived nitric 
oxide and in the consequent stimulation of angiogenesis 
[18–21]. While the activation of VEGFR signaling 
pathway stimulates the eNOS leading to the production 
of the potent vasodilator nitric oxide, the inhibition of 
VEGF signaling might lead to decrease the nitric oxide 
concentrations, resulting in vasoconstriction. In fact, 
the eNOS polymorphisms were found to be associated 
to a higher risk of developing grade 3 hypertension in a 
group of patients treated with sunitinib [22]. However, in 
literature there are few and uncertain data regarding the 
eNOS role in bevacizumab-induced toxicity.
This study was aimed at exploring the role of SNPs 
in IL-8 (c.-251T>A), eNOS (c.-786T>C, c.-894G>T) and 
VEGF-A (c.936C>T, c.958C>T, c.1154A>G, c.2578C>A) 
as potential biomarkers of efficacy and toxicity of 
bevacizumab in RAS mutated mCRC. Moreover, it was 




One-hundred and twenty consecutive patients were 
enrolled from 2007 to 2010 in the bevacizumab group, 
and their clinical characteristics are reported in Table 1. 
Forty-seven (39.2%) patients experienced a partial 
response and 8 (6.6%) a complete response, while 53 
(44.2%) had a stable disease and 12 (10%) had a PD. 
ORR was 45.8%, median PFS and median OS were 10 
and 37.6 months, respectively. Among the main clinical 
characteristics, only the number of metastatic sites showed 
a statistically significant correlation both with PFS and 
OS in the univariate analysis. In particular, patients with 
>2 metastatic sites had a PFS and an OS significantly 
shorter (PFS: 6 vs 9.2 months, HR: 2.31, 95% CI 1.72-
9.09, P=0.001; OS: 19.6 vs 29 months, HR: 2.77, 95% CI 
2.27-12.5, P<0.001) compared to those with < 2 metastatic 
sites. Considering only grade 3-4 toxicities, 11 (9.1%) 
patients developed hypertension, 3 (2.5%) bleeding, 3 
(2.5%) proteinuria, 3 (2.5%) venous thromboembolism, 1 
(0.8%) arterial thromboembolism and 1 (0.8%) acute renal 
failure.
Baseline characteristics of patients included in the 
control group are summarized in Table 2. Among the 
available clinical and pathological characteristics, only 
the number of metastatic sites showed a statistically 
significant correlation with OS in the univariate analysis 
(HR: 1.97, 95% CI 1.11-2.42, P=0.04). No significant 
correlation was found with PFS.
Correlation between genotypes and treatment 
outcomes
The genotyping analysis showed that all the SNPs 
were in Hardy-Weinberg Equilibrium and the relative 
frequencies of the selected and analysed SNPs are reported 
in Table 1 for bevacizumab group and in Table 2 for 
control group.
In the bevacizumab group, no statistically significant 
correlation was found between all analysed SNPs and 
ORR. Median PFS was significantly longer inpatients with 
IL-8 c.-251TT genotype as compared to those carrying 
the c.-251TA/AA genotypes (10 vs 8.2 months, HR: 
0.53, 95% CI 0.34-0.78, P=0.002) (Figure 1A and Table 
1); OS was also significantly longer inpatients with IL-8 
c.-251TT versus c.-251TA/TT (33 vs 26.3 months, HR: 
0.64, 95% CI 0.43-0.97, P=0.03) (Figure 1B and Table 
1). Patients with eNOS c.-251TG/GG genotype showed 
a significant lower PFS as compared to those carrying 
the c.-894TT genotype (9 vs 10 months, HR: 1.78, 95% 
CI 1.01-3.12; P=0.049), but did not show a significantly 
worse OS (27 vs 37 months, HR: 1.34, 95% CI 0.78-
2.23; P=0.2) (Table 1). All the other analyzed VEGF and 
eNOS SNPs failed to show any significant correlation with 
bevacizumab efficacy (Table 1).
The multivariate analysis was performed only 
with the significant clinical variable at the univariate 
analysis, i.e. number of metastatic sites. IL-8 c.-251AA/
AT genotype and presence of >2 metastatic sites retained 
their significant association with worse PFS (P=0.0006, 
HR: 1.8, 95% CI 1.18-2.8; and P=0.015, HR: 1.8, 95% CI 
1.12-2.9), while only the presence of >2 metastatic sites 
was independently associated with OS (P<0.001, HR: 2.4, 
95% CI 1.44-.4.28). The eNOS c-894TT genotype was no 
longer associated with PFS.
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Table 1: Patients and disease characteristics in bevacizumab-treated group 
Characteristics N120 %
Progression Free Survival Overall Survival
HR 95% CI P HR 95% CI P
Age, years ≤65 58 48.3
>65 62 51.7 1.30 0.87-2.29 0.59 1.27 0.67-2.75 0.55
Sex Male 74 61.7
Female 46 38.3 0.91 0.79-1.26 0.70 1.02 0.82-1.40 0.79
PS (ECOG) 0-1 113 94.2
2 7 5.8 1.35 0.79-1.91 0.68 1.47 0.85-2.21 0.65





52 43.4 0.61 0.39-1.13 0.11 0.65 0.38-1.52 0.37
Previous adjuvant 
treatment No 84 70.5
Yes 36 29.5 1.85 0.98-2.91 0.06 1.34 0.73-2.56 0.59
N. of metastatic 
sites ≤2 17 14.2
>2 103 85.8 2.31 1.72-9.09 0.001 2.77 2.27-12.5 <0.001
Mucinous histotype No 101 84.2
Yes 19 15.8 1.71 0.85-3.38 0.12 2.23 0.91-3.31 0.10
IL-8-251 T>A TT 43 36
rs4073 TA 50 42
AA 27 22
TT+TA vs AA 
(recessive model) 0.7 0.39-1.10 0.12 0.70 0.47-1.27 0.39
TT vs TA+AA 
(dominant model) 0.53 0.34-0.78 0.002 0.64 0.43-0.97 0.03
eNOS c.-786T>C TT 33 27.5
rs2070744 TC 60 50
CC 27 22.5
TT+TC vs CC 
(recessive model) 1.08 0.68-1.70 0.70 0.98 0.60-1.50 0.96
TT vs TC+CC 
(dominant model) 1.3 0.85-2.20 0.2 0.92 0.59-1.43 0.73
eNOS c.-894G>T GG 40 33
rs1799983 GT 64 54
TT 16 13
GG+GT vs TT 
(recessive model) 1.78 1.01-3.12 0.049 1.34 0.78-2.23 0.28
(Continued)
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Given the independent prognostic value of IL-8 
c.-251T>A, we assessed only this SNP in the historical 
control group of patients treated with FOLFOX only. 
No significant association with PFS or OS was detected 
(Figure 2A–2B), thus suggesting a potential predictive 
role of IL-8 SNP in patients treated we bevacizumab-based 
therapy.
Regarding toxicity, patients carrying the eNOS 
c.894TT genotype showed a statistically significant 
higher occurrence of hypertension and proteinuria when 
compared with GG + GT genotypes (P=0.0002) (Table 
3). All analyzed VEGF SNPs, IL-8 c.-251T>A and eNOS 
c.-786T>C failed to show any significant correlation with 
toxicity (Table 3).
Characteristics N120 %
Progression Free Survival Overall Survival
HR 95% CI P HR 95% CI P
GG vs GT+TT 
(dominant model) 1.11 1.70-1.72 0.56 1.15 0.75-1.77 0.50
VEGF-A 
c.936C>T* CC 43 61.4
rs3025039 CT 25 35.7
TT 2 2.9
CC + CT vs TT 
(recessive model) 1.04 0.25-4.35 0.955 1.39 0.23-7.96 0.74
CC vs CT + TT 
(dominat model) 1.38 0.35-5.38 0.642 1.60 0.27-8.47 0.64
VEGF-A 
c.958C>T* TT 43 61.4
rs833061 TC 14 20
CC 13 18.6
CC + CT vs TT 
(recessive model) 1.54 0.73-3.27 0.25 1.32 0.43-4.56 0.57
CC vs CT + TT 
(dominat model) 1.03 0.51-2.12 0.92 1.21 0.41-3.40 0.72
VEGF-A 
c.1154A>G* AA 32 45.7
rs1570360 AG 28 40
GG 10 14.3
AA + AG vs GG 
(recessive model) 1.83 0.86-3.45 0.07 1.81 0.85-3.12 0.11
AA vs AG + GG 
(dominat model) 1.23 0.75-1.32 0.45 1.32 0.65-1.36 0.56
VEGF-A 
c.2578C>A* CC 23 32.8
rs699947 CA 35 50
AA 12 17.2
CC + CA vs AA 
(recessive model) 1.09 0.64-1.93 0.78 1.31 0.58-2.99 0.55
CC vs CA + AA 
(dominant model) 1.15 0.55-2.23 0.69 1.39 0.48-3.89 0.544
Association of clinical and genomic characteristics with PFS and OS in bevacizumab group.
Bold: Clinical and SNPs characteristics. Italic and bold: statistical significant value.
*: Evaluated only in cohort 1 (Policlinico “Gemelli”).
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Functional significance of IL-8 c.251T>A for 
IL-8 serum levels
The median IL-8 serum level was 17 pg/mL (range 
1.3-309.1 pg/mL). Using the ROC curve analysis, the 
baseline IL-8 serum level cut-off was 18.25 pg/mL (area 
under the curve 0.71, Figure 3), which was quite similar 
to the median value. For this reason, patients showing a 
pre-treatment IL-8 serum level >18.25 were classified as 
IL-8-high, and patients with pre-treatment level lower than 
18.25 as IL-8-low. Median PFS and OS was significantly 
longer inIL-8-low patients as compared to IL-8-high 
patients (PFS: 10.9 vs 7.6 months, HR: 0.46, 95% CI 0.2-
0.76, P=0.005; OS: 30.7 vs 18.2 months, HR: 0.35, 95% 
CI 0.13-0.52, P<0.001; Figure 4A and 4B, respectively). 
At the multivariate analysis including number of 
metastatic sites, only IL-8 levels >18.25 pg/mL had an 
independent association with worse PFS (P=0.0014, HR: 
2.9, 95% CI 1.53-5.75) and OS (P=0.0002, HR: 3.2, 95% 
CI 1.7-5.9). Most importantly, serum levels of IL-8 in 
patients with IL-8 c.-251 TT genotype (median level 4.7 
pg/mL) was statistically lower as compared to those with 
TA (median level 29.3 pg/mL) or AA genotypes (median 
level 32.2 pg/ml) (H: 17.0, DF: 1 P<0.0001). Interestingly, 
in a parallel cohort of 50 healthy volunteers enrolled in the 
two Institutions as controls, the median IL-8 level was 4 
pg/mL (range 1.5-35.7 pg/mL) and presence of IL-8 SNP 
was not correlated with variations of serum levels (H: 3.4, 
DF: 1, P=0.67).
Table 2: Patients and disease characteristics in the control group (non-bevacizumab treated) 
Characteristics N112 %
Progression Free Survival Overall Survival
HR 95% CI P HR 95% CI P
Age, years ≤65 50 44.6
>65 62 55.4 1.2 0.71-2.11 0.51 1.23 0.61-2.72 0.52
Sex Male 58 51.7
Female 54 48.3 0.96 0.60-1.20 0.62 1.12 0.62-2.40 0.69
PS (ECOG) 0-1 102 91
2 10 9 1.15 0.66-2.10 0.66 1.77 0.86-3.21 0.43





50 44.7 0.69 0.39-1.23 0.18 0.65 0.29-1.61 0.37
Previous adjuvant No 79 70.5
Yes 33 29.5 1.91 0.97-3.11 0.06 1.25 0.67-2.91 0.61
N. of metastatic 
sites ≤2 17 14.1
>2 95 95.9 1.45 0.89-2.34 0.41 1.97 1.11-2.42 0.04
Mucinous histotype No 98 87.5
Yes 14 13.5 1.95 0.95-3.78 0.08 2.45 0.97-3.91 0.09
IL-8-251 T>A TT 38 33.9
rs4073 TA 45 40.1
AA 29 26
TT+TA vs AA 
(recessive model) 0.91 0.82-1.15 0.71 0.88 0.79-1.23 0.69
TT vs TA+AA 
(dominant model) 0.95 0.87-1.11 0.66 0.87 0.84-1.12 0.64
Association of clinical and genomic characteristics with PFS and OS in control group.
Bold: clinical and SNPs characteristics. Italic and bold: statistical significant value.
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Multipanel Figure: IL-8 SNPs and IL-8 serum levels influence PFS and OS. Kaplan-Meier plots for PFS in patients with 
IL-8 TT genotype versus heterozygous TA and polymorphic homozygous AA genotypes 1A. and in patients with IL-8-low serum level 
versus IL-8-high serum levels 4A. Kaplan-Meier plots for OS in patients with IL-8 TT genotype versus heterozygous TA and polymorphic 
homozygous AA genotypes 1B. and in patients with IL-8-low serum level versus IL-8-high serum levels 4B.
DISCUSSION
Several data on angiogenesis-related SNPs as 
predictive biomarkers of bevacizumab-based treatment 
were obtained from retrospective series and mostly 
involved VEGF [23]. For instance, VEGF c.-1498 TT 
SNP was associated with shorter PFS in mCRC patients 
treated with first-line FOLFIRI and bevacizumab [5]. 
However, a subsequent prospective validation study failed 
to confirm this hypothesis [6]. In line with these data, our 
study failed to show any significant impact of VEGF-A 
c.936C>T, c.958T>C, c.2578C>A and c.1154A>G. This 
study was aimed at showing whether SNPs related to 
VEGF-independent pathways might influence the efficacy 
of bevacizumab-based treatment in patients with RAS 
mutated mCRC. We focused on RAS mutated tumors since 
recent retrospective analyses of randomized trials seem to 
suggest a relatively smaller benefit from antiangiogenic 
agents in this patients’ subgroup with limited treatment 
options [24, 25]. Thus, the discovery of predictive 
biomarkers of efficacy of antiangiogenic treatments in 
this patient population is an unmet clinical need. It is well 
known that IL-8 can induce an angiogenic switch [7–10], 
allowing the “escape” from VEGF-targeted treatment [26]. 
We showed for the first time that the IL-8 polymorphism 
c.-251 “A” allele (dominant model) was associated 
with significantly shorter PFS and OS. The multivariate 






Figure 2: A-B. Kaplan-Meier plots for PFS (A) and OS (B) in control group patients with IL-8 TT genotype versus heterozygous TA and 




Table 3: Association of bevacizumab-related specific toxicity and candidate SNPs 
SNPs % P
IL-8 -251 T>A
TT+TA vs AA (recessive model) 14 vs 11.5 1
TT vs TA+AA (dominant model) 22 vs 10 0.06
eNOS -786 T>C
TT+TC vs CC (recessive model) 12 vs 21 0.22
TT vs TC+CC (dominant model) 12 vs 15 0.77
eNOS -894 G>T
GG+GT vs TT (recessive model) 8 vs 50 0.0002
GG vs GT+TT (dominant model) 5 vs 18 0.04
VEGF-A c.936C>T
CC + CT vs TT (recessive model) 10 vs 11 0.93
CC vs CT + TT (dominat model) 9.5 vs 10 0.98
VEGF-A c.958C>T
CC + CT vs TT (recessive model) 9 vs 12 0.73
CC vs CT + TT (dominat model) 8.5 vs 10 0.88
VEGF-A c.1154A>G
AA + AG vs GG (recessive model) 8 vs 9 0.92
AA vs AG + GG (dominat model) 10.5 vs 10 0.98
VEGF-A c.2578C>A
CC + CA vs AA (recessive model) 8 vs 8 1
CC vs CA + AA (dominat model) 9 vs 11 0.88
Relationship of polymorphisms with toxicity (hypertension and proteinuria).
Italic and bold: statistical significant value.
Figure 3: Receiver operating characteristics (ROC) curve analysis based on pre-treatment IL-8 serum levels. In this 
model sensitivity was 80% (95% CI: 74.7–82.8) and specificity was 56% (95% CI: 51.9–79.1). Area under the curve was 0.71, P=0.004.
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(P=0.01), but not with OS. This apparent discrepancy 
is not surprising, since PFS is widely accepted as a 
surrogate endpoint in first-line treatment, due to dilution 
of effects on OS by post-progression treatments. Similar 
observations on this IL-8 SNP were recently shown in 
patients with breast cancer treated with bevacizumab-
based chemotherapy [27, 28] and in exudative macular 
degeneration after bevacizumab treatment [29]. Since the 
“A” allele of the IL-8 SNP is associated with increased 
IL-8 production [11], a plausible biological explanation 
of our results is that patients carrying the A allele might 
benefit less from bevacizumab because of higher IL-8 
serum levels. In support of the role of IL-8 as factor 
of resistance to bevacizumab in metastatic colorectal 
cancer patients, a better clinical outcome was reported 
when IL-8 baseline levels were lower [30, 31]. On the 
contrary, Kopetz et al. showed that high IL-8 levels 
were associated with a shorter PFS and increased tumor 
volume [32]. In our study, we confirm that higher IL-8 
serum levels were associated with shorter PFS and OS. 
Moreover, we demonstrate for the first time the functional 
effect of IL-8 c.-251T>A SNP in cancer patients. In fact, 
we showed a statistically significant correlation between 
the polymorphic “A” allele and higher IL-8 serum levels, 
achieving the proof-of-concept that IL-8 might play 
a key role in the intrinsic resistance to bevacizumab in 
mCRC. Since the presence of polymorphic “A” allele did 
not influence IL-8 serum levels in healthy volunteers, we 
hypothesize that the pro-inflammatory state caused by 
the metastatic process may enhance IL-8 transcription in 
genetically predisposed patients. The genetic variation 
may also drive treatment-acquired resistance due to IL-
8-driven pro-inflammatory switch. In this scenario, IL-8 
may represent not only a prognostic biomarker in patients 
treated with anti-angiogenic therapy, but also a therapeutic 
target.
Regarding the eNOS gene, preclinical studies 
showed that eNOS c.-894G>T variant has a functional 
effect on eNOS protein, leading to a reduced NO 
production [17]. Recently, Ulivi et al. found that eNOS 
c.-894GT polymorphism may also predict efficacy of 
bevacizumab based-therapy in mCRC [33]. In our study, 
the multivariate analysis seemed to exclude a potential 
impact of eNOS on efficacy outcomes. However, we 
also focused on toxicity and showed that eNOS c.-894TT 
genotype was associated with significantly higher rate of 
grade 3-4 hypertension and proteinuria as compared to 
others. It must be pointed out that potential bevacizumab-
specific toxicities can be serious and contraindicate the use 
of this agent in patients at risk. Not surprisingly, alteration 
in the eNOS pathway may be correlated with the most 
frequent toxicities of bevacizumab, such as hypertension 
and proteinuria [34, 35]. In this context, in patients 
carrying eNOS c.-894 polymorphic “T” allele, lower 
basal levels of eNOS may increase the risk of hypertension 
induced by VEGF blockade [36–38].
Despite the biological consistency of our results, 
our study is limited by small sample size and retrospective 
evaluation. Therefore, it should be considered only as 
exploratory study. However, the absence of prognostic 
impact of IL-8 SNPs in the control group, allow to 
formulate the hypothesis that this factor may be a predictor 
of efficacy to bevacizumab-based treatment. However, 
the study of polymorphisms in alternative pathways of 
angiogenesis affords an original cue for future research 
on biomarkers predictive for bevacizumab activity and 
toxicity and may open the way to anti-IL-8 strategies to 




This study was conducted at two Italian Institutions: 
the cohort 1 comprised 70 patients treated at Policlinico 
“A. Gemelli” of Rome; the cohort 2 comprised 50 
patients treated at Fondazione IRCSS Istituto Nazionale 
dei Tumori of Milan. Both cohorts included only RAS 
mutated patients treated with first-line combination of 
FOLFOX6 plus bevacizumab (bevacizumab group). 
The study was approved by the local Ethics Committee 
and written informed consent was required before study 
procedures. Main inclusion criteria were: histologically 
confirmed diagnosis of mCRC, age ≥ 18 years, presence 
of at least one measurable lesion according to RECIST 
1.0, no prior treatments for metastatic disease, ECOG 
performance status between 0 and 2, and acceptable bone 
marrow, liver and renal functions. We excluded patients 
with serious concomitant illness that could affect the 
treatment outcome or survival. Treatment was continued 
until disease progression, occurrence of unacceptable 
toxicity or consent withdrawal. A historical cohort of 112 
RAS mutated patients treated at Policlinico “A. Gemelli”, 
from January 2002 until November 2007, with first-line 
FOLFOX alone served as control group.
Single nucleotide polymorphisms genotyping
The following SNPs were analysed: IL-8 c.-
251T>A; eNOS c.-786T>C and c.-894G>T; VEGF-A 
c.936C>T, c.958T>C, c.1154A>G and c.2578C>A. 
Given their promising results, IL-8 and eNOS SNPs were 
analyzed in the whole series. VEGF SNPs were explored 
exclusively in cohort 1 and, given the non significant 
results in this training set, further analyses on the whole 
series was abandoned. Blood samples were stored at -20°C 
and used for molecular analyses. DNA wasi extracted with 
Maxwell (R) 16 System from Promega (Madison, USA), 
using a specific kit (AS1010-Maxwell 16 Blood DNA 
purification kit) that allows the simultaneous extraction 
of DNA from 16 blood samples. Samples were analysed 
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using the polymerase chain reaction-restriction fragment 
length polymorphism (PCR-RFLP) technique. Once 
extracted, DNA from each sample was amplified by 
PCR with primers specific for each SNP. PCR products 
were digested by restriction enzymes (FastDigest ® 
Restriction Enzymes, Fermentas, USA) specific for each 
polymorphism. The fragments obtained from each cut 
were then separated on the basis of molecular weight by 
electrophoresis on 3% agarose gel in 1x TAE buffer (40 
mM tris [pH 7.6], 20 mM acetic acid and 1 mM EDTA), 
colored with ethidium bromide and visualized with 
ultraviolet light. The genotyping analysis was performed 
by laboratory personnel and patient clinical outcomes 
were blinded to laboratorists.
IL-8 serum levels quantification
Pre-treatment serum samples were available only 
for patients in cohort 2. IL-8 levels were quantified by 
ELISA, with the use of a Quantikine ELISA Human 
CXCL8/IL-8 Immunoassay kit (R&D Systems a biotechne 
brand, Minneapolis, MN), according to the manufacturer’s 
protocol.
Statistical analysis
All polymorphisms were examined for deviation 
from Hardy-Weinberg equilibrium (HWE) by comparing 
actual allelic distributions with those expected from 
HWE using a χ2-test. No formal statistical hypothesis 
testing neither adjustment for multiple comparison were 
performed because this study was exploratory in nature 
and aimed to generate hypothesis for future studies. 
Therefore, only descriptive statistics were derived. 
Progression free survival (PFS) was defined as the 
time from treatment start to progressive disease (PD) 
or death. Overall survival (OS) was defined as the time 
from treatment start to death or last follow up. Overall 
response rate (ORR) was evaluated by RECIST version 
1.0 criteria and tumor assessments were repeated every 
12 weeks until PD. Bevacizumab-related toxicities were 
assessed at each cycle according to National Cancer 
Institute Common Toxicity Criteria (version 3.0). The 
association between each gene polymorphism with 
response and toxicity was evaluated by Fisher’s exact 
test. The Kaplan-Meier method and log-rank test were 
used to estimate the role of each variable in predicting 
the hazard ratio (HR) for disease progression and death. 
Clinical variables including: age (≤65 vs>65), histology 
(mucinous versus non-mucinous), primary site, ECOG 
performance status (0-1 vs 2), number of metastatic 
sites (≤2 vs >2) and previous adjuvant treatment. The 
correlation of clinical characteristics and SNP status 
with survival was assessed in univariate analyses 
according to the dominant and recessive genetic models. 
Cox proportional hazard model was adopted in the 
multivariate analysis, including as covariates variables 
significantly correlated with survival in the univariate 
analyses (P<0.05). Receiver operating characteristics 
(ROC) curve analysis was performed to determine a 
cutoff value for pre-treatment IL-8 levels using median 
PFS as endpoint. The Kruskal-Wallis test was used to 
correlate IL-8 serum levels with SNP -251 T/A. All 
analyses were two-sided, and statistical significance was 
defined by a P value of <0.05. Analyses were performed 
using SPSS for MAC (version 22.0.0).
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